Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression - PubMed (original) (raw)
. 2013 Jan;182(1):132-41.
doi: 10.1016/j.ajpath.2012.09.016. Epub 2012 Nov 14.
Affiliations
- PMID: 23159951
- DOI: 10.1016/j.ajpath.2012.09.016
Free article
Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression
Ayako Ojima et al. Am J Pathol. 2013 Jan.
Free article
Abstract
Advanced glycation end products (AGEs) and their receptor (RAGE) play a role in diabetic nephropathy. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase, contributes to diabetic nephropathy. We have found that glucagon-like peptide-1 (GLP-1) inhibits the AGE-induced inflammatory reactions in endothelial cells. However, effects of GLP-1 on the AGE-RAGE-ADMA axis are unknown. This study examined the effects of GLP-1 on reactive oxygen species (ROS) generation, gene expression of protein arginine methyltransfetase-1 (PRMT-1), an enzyme that mainly generates ADMA, and ADMA levels in human proximal tubular cells. Streptozotocin-induced diabetic rats received continuous i.p. infusion of 0.3 μg of vehicle or 1.5 μg of the GLP-1 analog exendin-4 per kilogram of body weight for 2 weeks. We further investigated whether and how exendin-4 treatment reduced ADMA levels and renal damage in streptozotocin-induced diabetic rats. GLP-1 inhibited the AGE-induced RAGE and PRMT-1 gene expression, ROS, and ADMA generation in tubular cells, which were blocked by small-interfering RNAs raised against GLP-1 receptor. Exendin-4 treatment decreased gene expression of Rage, Prmt-1, Icam-1, and Mcp-1 and ADMA level; reduced urinary excretions of 8-hydroxy-2'-deoxyguanosine and albumin; and improved histopathologic changes of the kidney in diabetic rats. Our present study suggests that GLP-1 receptor agonist may inhibit the AGE-RAGE-mediated ADMA generation by suppressing PRMT-1 expression via inhibition of ROS generation, thereby protecting against the development and progression of diabetic nephropathy.
Copyright © 2013 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Similar articles
- Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level.
Ishibashi Y, Yamagishi S, Matsui T, Ohta K, Tanoue R, Takeuchi M, Ueda S, Nakamura K, Okuda S. Ishibashi Y, et al. Metabolism. 2012 Aug;61(8):1067-72. doi: 10.1016/j.metabol.2012.01.006. Epub 2012 Mar 3. Metabolism. 2012. PMID: 22386936 - Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis.
Maeda S, Matsui T, Takeuchi M, Yoshida Y, Yamakawa R, Fukami K, Yamagishi S. Maeda S, et al. Pharmacol Res. 2011 Mar;63(3):241-8. doi: 10.1016/j.phrs.2010.11.008. Epub 2010 Nov 27. Pharmacol Res. 2011. PMID: 21115116 - Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level.
Ishibashi Y, Nishino Y, Matsui T, Takeuchi M, Yamagishi S. Ishibashi Y, et al. Metabolism. 2011 Sep;60(9):1271-7. doi: 10.1016/j.metabol.2011.01.010. Epub 2011 Mar 8. Metabolism. 2011. PMID: 21388644 - Can Targeting the Incretin Pathway Dampen RAGE-Mediated Events in Diabetic Nephropathy?
Sourris KC, Yao H, Jerums G, Cooper ME, Ekinci EI, Coughlan MT. Sourris KC, et al. Curr Drug Targets. 2016;17(11):1252-64. doi: 10.2174/1389450116666150722141418. Curr Drug Targets. 2016. PMID: 26201485 Review. - Intestinal regulation of urinary sodium excretion and the pathophysiology of diabetic kidney disease: a focus on glucagon-like peptide 1 and dipeptidyl peptidase 4.
Vallon V, Docherty NG. Vallon V, et al. Exp Physiol. 2014 Sep;99(9):1140-5. doi: 10.1113/expphysiol.2014.078766. Epub 2014 Aug 1. Exp Physiol. 2014. PMID: 25085841 Free PMC article. Review.
Cited by
- Cardiovascular diseases or type 2 diabetes mellitus and chronic airway diseases: mutual pharmacological interferences.
Cazzola M, Rogliani P, Ora J, Calzetta L, Matera MG. Cazzola M, et al. Ther Adv Chronic Dis. 2023 May 31;14:20406223231171556. doi: 10.1177/20406223231171556. eCollection 2023. Ther Adv Chronic Dis. 2023. PMID: 37284143 Free PMC article. Review. - Protective Effects of Epigallocatechin-3-Gallate from Green Tea in Various Kidney Diseases.
Kanlaya R, Thongboonkerd V. Kanlaya R, et al. Adv Nutr. 2019 Jan 1;10(1):112-121. doi: 10.1093/advances/nmy077. Adv Nutr. 2019. PMID: 30615092 Free PMC article. - Exendin-4 Improves Diabetic Kidney Disease in C57BL/6 Mice Independent of Brown Adipose Tissue Activation.
Fang S, Cai Y, Lyu F, Zhang H, Wu C, Zeng Y, Fan C, Zou S, Zhang Y, Li P, Wang L, YaomingXue, Guan M. Fang S, et al. J Diabetes Res. 2020 Feb 3;2020:9084567. doi: 10.1155/2020/9084567. eCollection 2020. J Diabetes Res. 2020. PMID: 32090125 Free PMC article. - Paradoxical effects of heme arginate on survival of myocutaneous flaps.
Edmunds MC, Czopek A, Wigmore SJ, Kluth DC. Edmunds MC, et al. Am J Physiol Regul Integr Comp Physiol. 2014 Jan 1;306(1):R10-22. doi: 10.1152/ajpregu.00240.2013. Epub 2013 Oct 2. Am J Physiol Regul Integr Comp Physiol. 2014. PMID: 24089372 Free PMC article. - Tubulointerstitial disease in diabetic nephropathy.
Tonolo G, Cherchi S. Tonolo G, et al. Int J Nephrol Renovasc Dis. 2014 Mar 21;7:107-15. doi: 10.2147/IJNRD.S37883. eCollection 2014. Int J Nephrol Renovasc Dis. 2014. PMID: 24711709 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous